ERBB2 and breast cancer: The correlation between UCHL1 expression and RFS in patients with ER- HER2+ BC was opposite, probably owing to the limited number of patients with this subtype of BC, or the effective targeted drug (trastuzumab) for anti-HER2 treatment.